Category: Treatment

The Attorney General’s office finds no legal basis for a state medical licensure board to discipline a licensed physician for exercising sound judgement and safely prescribing an FDA-approved drug – like ivermectin or hydroxychloroquine – for the off-label purpose of treating a patient with COVID-19 Attorney General John O’Connor I stand behind doctors who believe it is in their patients’ best interests to receive ivermectin and hydroxychloroquine Our healthcare professionals should have every tool available to combat COVID-19. Public safety demands this. Physicians who prescribe medications and follow the law should not fear disciplinary action for prescribing such drugs The Attorney General’s office neither condones nor condemns a specific course of treatment for COVID-19. Our office maintains that proper healthcare decisions are to be made between a patient and his or her physician, and the government should not interfere with their relationship. FDA position unchanged…

A Manhattan judge says she won’t force a hospital to give an ailing post-COVID-19 patient the controversial drug ivermectin after the man’s wife sued for the non-FDA-approved treatment, according to a new ruling. Erika Quintero-Sherry brought a civil case against Mount Sinai Hospital on Jan. 26 seeking an emergency order to have the drug given to husband Benjamin Chernyavsky — who’s been “on death’s doorstep” after contracting the virus last month. Following two days of hearings in the case last week, including testimony from two Mount Sinai doctors, Manhattan Supreme Court Justice Lynn Kotler said she wouldn’t grant the emergency request to force the hospital’s staff to administer the risky drug based on Quintero-Sherry’s “paltry” evidence and going against Chernyavsky’s treating doctor’s recommendations, as well as the recommendations from the medical community at large.

“Plaintiff would have this court order defendants to administer an unapproved treatment to her husband against defendants’ medical opinion rendered in the independent exercise of their professional judgment,” Kotler’s Tuesday decision reads. “Indeed, the record reveals that if prescribed ivermectin, Mr. Chernyavsky’s condition may very well worsen.” “The prevailing view in the medical community … is that ivermectin should not be prescribed,” Kotler said, noting that that is the opinion of the FDA, the Centers for Disease Control and Prevention and many other medical associations. “Plaintiff’s paltry showing is insufficient to overcome the mountain of evidence showing that ivermectin is not presently safe or effective in the treatment of COVID-19,” Kotler wrote. Kotler also noted testimony from a Mount Sinai doctor that Chernyavsky was likely no longer infected with COVID-19, but rather “now must recover from the effects the disease has had on his body and organs.” While the judge did not grant the emergency motion, the rest of the case must still play out in court. “Mount Sinai is committed to providing the highest quality care to all of our patients and uses evidence-based data in our clinical decision-making,” a hospital spokesperson said in a statement. “We are pleased with the judge’s decision to sustain the decis Quintero-Sherry’s lawyers did not immediately return a request for comment. The 60-year-old father of five contracted the virus on Jan. 9 and was eventually put into a medically induced coma and also placed on a ventilator. Quintero-Sherry argued that her husband had a less than 20 percent chance of survival. The wife also said that since the hospital had exhausted all the COVID-19 protocols for patients, rather than continuing the alleged “wait-and-see” approach, there was nothing to lose by treating her husband with ivermectin. The drug — a horse and cow de-wormer — raised headlines during the pandemic after COVID patients were reportedly using it to treat the bug.

It’s approved for human use to treat parasitic infections, head lice and some skin conditions, according to the FDA.

“The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals,” the agency says on its website. ions of our clinicians to refrain from using ivermectin for treatment of COVID -19.” “Ivermectin has not been shown to be safe nor effective for the treatment or prevention of COVID-19, and the FDA has not authorized or approved this treatment for this use,” the statement continued. NN: Ivermectin a Nobel prize winning drug designated by the WHO as an essential medicine. Countless studies have shown it to be a powerful antiviral inhibiting the ACEII receptor. It has been administered in over a billion doses and is one of the safest medicines ever developed……

Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. COVID-19 patients face risks after hospital discharge People face substantially higher risks of health problems in the months after being discharged from the hospital following a bout of COVID-19, researchers in England found. Comparing 24,673 COVID-19 patients who survived at least a week after hospital discharge and 123,362 similarly aged people in the general population, they found the COVID-19 survivors had twice the risk of hospital admission or death during the next 10 months. Compared with 16,058 patients who had been hospitalized for influenza, the COVID-19 patients were 37% more likely to be readmitted or die due to their initial infection or other lower respiratory tract infection, and 37% more likely to experience cognitive-related admission or death, researchers reported in PLOS Medicine. COVID-19 patients with dementia who survived hospitalization were at particularly high risk for death in the months afterward, according to the report. “Large numbers of people have been hospitalized with COVID-19… and the raised risks of death and readmission… could significantly impact public health and resources,” the researchers wrote. “Risks might be minimized or mitigated by increasing monitoring of patients in the months following hospital discharge, and greater awareness among patients and clinicians of potential problems.” When the SARS-CoV-2 spike breaks into cells via a “gateway” protein on cell surfaces called ACE2, a second cell-surface protein called vimentin facilitates the process, possibly by serving as a bridge between the virus and ACE2, new research suggests. Using sophisticated analytical chemistry techniques, the researchers observed that vimentin attaches itself to the spike protein on the surface of the coronavirus. Based on their findings, they believe it might also attach itself to the ACE2 protein. In test tube experiments, they saw that when both vimentin and ACE2 are present, entry of the virus into the cells that line the blood vessels increases. They also found that depletion of vimentin significantly reduces SARS-CoV-2 infection of human cells, according to a report published in PNAS. Study coauthor Nader Rahimi of Boston University School of Medicine said his team found that a monoclonal antibody developed by Abcam Plc blocked vimentin from binding to the virus, in turn keeping the virus from entering the cells. Vimentin is also found on cells lining the heart, the air sacs of the lungs, and the nose, the researchers noted. “Establishing the full range of the involvement of vimentin in viral entry and infection will require further investigations,” the researchers said in a statement. They said they hope their findings will lead to new antiviral drugs that keep both ACE2 and vimentin from interacting with the coronavirus. NN: As your librarian I keep coming back to Ivermectin and other antivirals like Niclosanmide which is over the counter in many places so talk to your heath professional. And of course get fully vaccinated. See the latest research from NCBI below.

Niclosamide PDF Download

New Pfizer antiviral and ivermectin, a pharmacodynamic analysis New Pfizer antiviral, PF-07321332, C₂₃H₃₂F₃N₅O₄ PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease, https://www.pfizer.com/news/press-rel… So, what is a protease? So what is a protease inhibitor? And, what is 3CL? Chymotrypsin-like protease (3CL main protease, or 3CL Mpro) Identification of SARS-CoV‑2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening (3rd September 2020) https://pubs.acs.org/doi/abs/10.1021/… The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection https://pubs.rsc.org/en/content/artic… the strength and persistency of the interaction between IVE and the binding site of 3CLpro indicate that a partial inhibition of the catalytic activity could have place as the drug interacts with the main subdomains that define the enzyme binding pocket: Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents https://www.nature.com/articles/s4200… as shown in Fig. 4, out of 13 OTDs only ivermectin completely blocked ( more than 80%) the 3CLpro activity at 50 µM concentration. Development, validation, and approval of COVID-19 specific drugs takes years. Therefore, the idea of drug repositioning, also known as repurposing, is an important strategy to control the sudden outbreak of life-threatening infectious agents that spread rapidly. Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study https://pubs.rsc.org/en/content/artic… From the docking analysis, ivermectin showed the highest docking score with an average energy of −8.5 kcal mol−1 among all the compounds. Remdesivir showed the lowest binding energy and highest docking score of −9.9 kcal mol−1 https://bnf.nice.org.uk/medicinal-for… Ritonavir, C37H48N6O5S2 Ivermectin, C48H74O14 Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach https://www.ncbi.nlm.nih.gov/pmc/arti… We have documented an intense binding of both ivermectin B1a and B1b isomer to the main protease with subsequent energy (ETot-) values of -384.56 and -408.6. PF-07321332 is designed to block the activity of the SARS-CoV-2-3CL protease, https://www.pfizer.com/news/press-rel… Risk of virus developing resistance to PF-07321332 Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2 https://www.frontiersin.org/articles/… With SARS-CoV-2 S Spike protein Ivermectin showed high binding affinity to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2. In agreement to our findings, ivermectin was found to be docked between the viral spike and the ACE2 receptor Binding Interactions of Selected Drugs With Human TMPRSS2 Protein (ACE2 protein) The docking results revealed that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −174.971) and protein–ligand interactions Binding Interactions of Selected Drugs With Human ACE-2 Protein that ivermectin showed the highest binding affinity to the active site of the protein (MolDock score −159.754) and protein–ligand interactions With SARS-CoV-2 S Glycoprotein Ivermectin showed the highest binding affinity to the predicted active site of the protein With SARS-CoV-2 Nsp14 Protein ivermectin showed the highest binding affinity (MolDock score −212.265) and protein–ligand interactions Binding Interactions of Selected Drugs With SARS-CoV-2 PLpro Ivermectin showed the highest binding affinity to the predicted active site of the protein (MolDock score −180.765) and protein–ligand interactions.

Ever since the COVID-19 pandemic began, scientists have searched for an easily accessible medication that can help treat the virus. Merck recently announced that it is planning to seek an emergency use authorization from the Food and Drug Administration for its antiviral, molnupiravir. And now, it seems, there’s another promising—but surprising— medication that may be helpful in keeping high-risk patients out of the hospital: the antidepressant fluvoxamine. A large, placebo-controlled, randomized clinical trial published in The Lancet on Wednesday analyzed the effects of the drug, which is currently used to treat obsessive-compulsive disorder and depression, on patients with COVID-19. The researchers randomly assigned 741 patients fluvoxamine and 756 were given a placebo. The researchers discovered that the group that was given fluvoxamine were 1/3 less likely to need to be hospitalized or undergo prolonged medical observation than the placebo group. Some patients with COVID-19 stopped taking fluvoxamine over side effects but, in those who continued with the medication, one patient died compared to 12 who were given the placebo. Fluvoxamine also lowered the risk of patients being hospitalized by 2/3. Continue reading “Fluvoxamine cheap antidepressant shows promise fighting early stage covid19”

Oct 12 (Reuters) – The European Union may consider signing a supply deal with U.S. drugmaker Merck for its experimental COVID-19 pill, but only after the company starts the process of seeking approval for the drug in the bloc, a senior EU official said on Tuesday. The oral antiviral treatment molnupiravir has been developed with Ridgeback Biotherapeutics. On Monday Merck applied for emergency use authorisation in the United States, which has already secured 1.7 million courses of molnupiravir at a price of $700 per course. The EU would consider a joint procurement of molnupiravir, “if Merck engages with EMA”, the EU official told Reuters, referring to the European Medicines Agency. Throughout the pandemic, the EU has signed advance purchase deals for experimental vaccines and drugs against the new virus before companies applied to EMA, but the official said that approach had now changed because the 27-nation bloc has entered a new phase in the health emergency. Continue reading “EU may consider deal on Merck’s COVID pill after approval procedure begins”